NCT07020117 - A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

August 22, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2032

Conditions

Urothelial Carcinoma BladderTriple Negative Breast Cancer (TNBC)Hormone Receptor Positive Breast AdenocarcinomaNon Small Cell Lung CancerCervical AdenocarcinomaColorectal AdenocarcinomaHead and Neck Cancer

Interventions

DRUG

[225Ac]Ac-AKY-1189 (therapeutic)

\[225Ac\]Ac-AKY-1189 Injection

DRUG

[64Cu]Cu-AKY-1189 (imaging)

\[64Cu\]Cu-AKY-1189 Injection

Trial Locations (4)

33165

RECRUITING

Biogenix Molecular, LLC, Miami

49503

RECRUITING

BAMF Health, Grand Rapids

52242

RECRUITING

University of Iowa, Iowa City

77030

RECRUITING

MD Anderson Cancer Center, Houston